Traditionally, the field of synthetic biology has led to the development of intricate cellular biosensors for various applications. However, the ability to detect specific extracellular DNA sequences and mutations remained an uncharted territory until now. By capitalising on the unique properties of Acinetobacter baylyi, researchers have created a new paradigm in disease detection through their innovative cellular assay called CRISPR-discriminated horizontal gene transfer (CATCH). This technique enables the bacteria to selectively identify and integrate target DNA, paving the way for precise and non-invasive cancer detection.

The potential of CATCH technology transcends detection. By strategically placing engineered biosensors within the gastrointestinal tract, researchers can capture and preserve released DNA before degradation, a crucial advantage over traditional methods. Furthermore, the versatility of CATCH allows it to be tailored to detect a wide range of DNA sequences, making it a promising tool for identifying various genetic abnormalities and mutations associated with different diseases.

While the application of this technology in a clinical setting requires further refinement and evaluation, its impact on the field of disease detection and treatment is undeniable. As CATCH evolves and matures, it promises to revolutionise our approach to diagnosing and treating cancer and other ailments. This innovation not only underscores the potential of synthetic biology but also heralds a new era in personalised and targeted medical interventions, where bacteria act as vigilant DNA detectives, helping us unlock the mysteries of genetic diseases.

Engineered bacteria detect tumor DNA

Robert M Cooper, Josephine A Wright, Jia Q Ng, Jarrad M Goyne, Nobumi Suzuki, Young K Lee, Mari Ichinose, Georgette Radford, Feargal J Ryan, Shalni Kumar, Elaine M Thomas, Laura Vrbanac, Rob Knight, Susan L Woods, Daniel L Worthley, Jeff Hasty.